Please assess the completion status of the following clinical trial:

Trial Title: Safety and Efficacy Study of Teduglutide in Subjects With Short Bowel Syndrome Who Completed Protocol CL0600-004 (NCT00081458)

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: TRIPLE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~At dosing week 24 of protocol CL0600-004 (NCT00081458), subjects will be reviewed for their participation in this study.~Subjects who meet all of the following criteria can be enrolled in this study:~* Signed and dated informed consent form (ICF) to participate before any study-related procedures are performed~* Completion of protocol CL0600-004 (NCT00081458)~Exclusion Criteria:~* History of cancer or clinically significant lymphoproliferative disease with fewer than 5 years documented disease-free state~* History of alcohol or drug abuse (within previous year)~* Prior use of native glucagon-like peptide 2 (GLP-2) within 3 months of screening visit~* Pregnant or lactating women~* Any condition or circumstance, which in the investigator's opinion would put the subject at any undue risk, prevent completion of the study, or interfere with analysis of the study results

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- teduglutide 0.05 mg/kg/d (Type: EXPERIMENTAL): 0.05 mg/kg/d teduglutide subcutaneous injection
- teduglutide 0.10 mg/kg/d (Type: EXPERIMENTAL): 0.10 mg/kg/d teduglutide subcutaneous injection

Based on this trial design, predict the completion outcome and termination type (if applicable).